| P50 | author | Lisa J Moran | Q38544869 |
| P2093 | author name string | C Meyer | |
| | H J Teede | |
| | S K Hutchison | |
| | S Zoungas | |
| P2860 | cites work | Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association | Q22241929 |
| | Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 |
| | A comparative evaluation of waist circumference, waist-to-hip ratio and body mass index as indicators of cardiovascular risk factors. The Canadian Heart Health Surveys | Q28189814 |
| | Relationship between aldosterone and progesterone in the human menstrual cycle | Q28254112 |
| | Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis | Q28257443 |
| | Leptin regulates proinflammatory immune responses | Q28565340 |
| | Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome | Q29619211 |
| | Transient increase in obese gene expression after food intake or insulin administration | Q34296141 |
| | Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women | Q34489447 |
| | Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute spons | Q36536790 |
| | Indices of low-grade inflammation in polycystic ovary syndrome | Q36739203 |
| | The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. | Q37005382 |
| | The glycemic index: methodology and clinical implications | Q37513311 |
| | Prevalence of the metabolic syndrome in Asian women with polycystic ovary syndrome: using the International Diabetes Federation criteria | Q38302430 |
| | Leptin concentrations in the polycystic ovary syndrome | Q38345598 |
| | Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling? | Q40181783 |
| | Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes | Q40219535 |
| | Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes | Q40515404 |
| | Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance | Q42517944 |
| | Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes | Q42805075 |
| | Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein | Q42811136 |
| | Effect of cyproterone acetate on active and inactive renin secretion in patients with precocious puberty and genetic short stature | Q43587374 |
| | Circulating leptin concentrations and ovarian function in polycystic ovary syndrome | Q43715723 |
| | Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women with polycystic ovary syndrome | Q44127874 |
| | Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study | Q44196283 |
| | Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study | Q44273259 |
| | Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. | Q44435388 |
| | Effect of two modes of antiandrogen treatment on insulin sensitivity and serum leptin in women with PCOS. | Q44456606 |
| | Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion | Q44725156 |
| | Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity | Q44835001 |
| | The polycystic ovary syndrome per se is not associated with increased chronic inflammation | Q44841327 |
| | Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation | Q45142836 |
| | Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. | Q45173115 |
| | Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src | Q45256399 |
| | Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction | Q45304577 |
| | Determinants of circulating adiponectin in women with polycystic ovary syndrome. | Q46533669 |
| | Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome | Q46609404 |
| | Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes | Q46611349 |
| | Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease | Q46620961 |
| | The leptin to adiponectin ratio is a good biomarker for the prevalence of metabolic syndrome, dependent on visceral fat accumulation and endurance fitness in obese patients with diabetes mellitus | Q46679307 |
| | Adiponectin concentrations during menstrual cycle | Q46738807 |
| | Leptin : adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes : relationship of the index to carotid intima-media thickness | Q46784366 |
| | Serum levels of leptin and homocysteine in women with polycystic ovary syndrome and its relationship to endocrine, clinical and metabolic parameters | Q46784643 |
| | The ratio of leptin to adiponectin can be used as an index of insulin resistance | Q46811508 |
| | Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome | Q46843580 |
| | C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome | Q47288137 |
| | Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. | Q47587316 |
| | Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome | Q47856014 |
| | Circulating leptin concentrations in polycystic ovary syndrome: relation to anthropometric and metabolic parameters. | Q50957787 |
| | Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. | Q51463661 |
| | Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome. | Q51469698 |
| | Endothelial dysfunction in PCOS: role of obesity and adipose hormones. | Q51501142 |
| | Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. | Q51554374 |
| | Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). | Q51555318 |
| | Inflammatory markers and visceral fat are inversely associated with maximal oxygen consumption in women with polycystic ovary syndrome (PCOS) | Q62222767 |
| | Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin | Q71432826 |
| | Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome | Q71788692 |
| | Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome | Q79138632 |
| | Serum leptin and C-reactive protein levels in the physiological spontaneous menstrual cycle in reproductive age women | Q79774468 |
| | Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome | Q79842884 |
| | Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome | Q80185084 |
| | The adiponectin-to-leptin ratio in women with polycystic ovary syndrome: relation to insulin resistance and proinflammatory markers | Q80355853 |
| | Metformin treatment does not affect total leptin levels and free leptin index in obese patients with polycystic ovary syndrome | Q80688687 |
| | Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients | Q80795154 |
| | Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study | Q83288961 |
| P433 | issue | 4 | |
| P921 | main subject | obesity | Q12174 |
| | polycystic ovary syndrome | Q500816 |
| | polycystic ovary | Q5547896 |
| P304 | page(s) | 258-265 | |
| P577 | publication date | 2009-10-15 | |
| P1433 | published in | Journal of Endocrinological Investigation | Q15766847 |
| P1476 | title | Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention | |
| P478 | volume | 33 | |